All Products La Merie Publishing

Show Cart

La Merie Publishing

Results 41 - 60 of 151

Oct 2016 CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

200.00 €

Sep 2016 August 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

200.00 €

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

3,000.00 €

4,500.00 €

(Discount: 33.33%)

Aug 2016 CD123: a paradigmatic target for immunotherapeutic treatment modalities

700.00 €

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

500.00 €

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

2,450.00 €

Jun 2016 Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016

250.00 €

Jun 2016 Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

3,100.00 €

6,200.00 €

(Discount: 50.00%)

Jun 2016 Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

500.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

250.00 €

May 2016 Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

1,300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

500.00 €

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

2,050.00 €

Apr 2016 Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

300.00 €

Currencies

Shopping cart

Cart empty

Latest report

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Latest Target Pipeline

CD40 Antagonists & CD40L Inhibitors – Target Pipeline List 08/2018

Currencies

Shopping cart

Cart empty

Latest report

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

La Merie Publishing

Oct 2016 CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

Sep 2016 Competitor Analysis Immunotoxins 2016

Sep 2016 August 2016 R&D and Business Tracker for Antibody-Drug Conjugates

Sep 2016 August 2016 R&D and Business Tracker for Bispecific Antibodies

Sep 2016 August 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

Aug 2016 CD123: a paradigmatic target for immunotherapeutic treatment modalities

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

Jun 2016 Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016

Jun 2016 Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

Jun 2016 Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

May 2016 Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Apr 2016 Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Currencies

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Currencies

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing